NOTICE OF UPGRADE
Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022
SEARCH LISTED COMPANY
Any AUS or NZ company
SEARCH PRIVATE COMPANY
SEARCH FUNDS
Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
12 March 2025
| Name: | ANTEO DIAGNOSTICS LIMITED (ADO) (This company subsequently changed its name to ANTEOTECH LTD. You should refer to that name for Status.) | |||||||||
| Date of Listing: | 07 April 2000 | |||||||||
| Subsequent Names: |
| |||||||||
| Former Names: |
|
Stock Exchange Status: (updated daily)
This company subsequently changed its name to ANTEOTECH LTD. You should refer to that name for Stock Exchange Status.Legal Status: (updated monthly)
This company subsequently changed its name to ANTEOTECH LTD. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status: (updated at least quarterly)
This company subsequently changed its name and is now ANTEOTECH LTD. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| FROM | TO | |
| ANTEOTECH LTD | 15/11/2019 | |
| ANTEO DIAGNOSTICS LIMITED | 25/11/2008 | 15/11/2019 |
| BIOLAYER CORPORATION LIMITED | 23/01/2006 | 25/11/2008 |
| S.S.H. MEDICAL LIMITED | 23/01/2006 |
Boardroom Pty Ltd
Level 8, 210 George Street, Sydney NSW 2000
Tel : +61 2 9290 9600 or 1300 737 760
Fax : +61 2 9279 0664 or 1300 653 459
RegistryWebsite RegistryEmail
Expand this box to read and print
name changed to AnteoTech Ltd | 15/11/2019 |
The suspension of trading in the securities of Anteo Diagnostics Limited will be lifted prior to the commencement of trading on Monday, 9 October 2017 following lodgement of the Company's Annual Report for the full year ended 30 June 2017. | 06/10/2017 |
The company lodges its Annual Report to shareholders 30 June 2017. | 06/10/2017 |
The company releases its Corporate Governance Statement. | 06/10/2017 |
The company releases an Appendix 4G. | 06/10/2017 |
The securities of the company will be suspended from official quotation from the commencement of trading today, 2 October 2017, following failure to lodge its full year accounts for the period ended 30 June 2017 in accordance with ASX listing rules. | 02/10/2017 |
The suspension of trading in the securities of Anteo Diagnostics Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding revised terms in relation to the acquisition of DIAsource ImmunoAssays S.A by the Company. Security Code: ADO | 06/01/2016 |
Anteo Diagnostics Limited has agreed revised terms to acquire 100% of the equity in global specialty diagnostics company, DIAsource ImmunoAssays S.A. (Belgium), in line with previously announced acquisition. The originally announced Purchase Price of €15.4m (A$23.7m), with a two year earn out to vendors, subject to achievement of financial business targets (up to a maximum of €7.3m) remains the same. The Purchase Price consideration (€15.4m) is now to be paid 50% in cash up-front (€7.7m) and the balance (€7.7m) to be paid via a deferred payment plan. | 06/01/2016 |
The securities of Anteo Diagnostics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to the proposed revision of terms of the proposed DIAsource acquisition. Security Code: ADO | 05/01/2016 |
name changed from Biolayer Corporation Limited | 25/11/2008 |
name changed to AnteoTech Ltd | 15/11/2019 |
The suspension of trading in the securities of Anteo Diagnostics Limited will be lifted prior to the commencement of trading on Monday, 9 October 2017 following lodgement of the Company's Annual Report for the full year ended 30 June 2017. | 06/10/2017 |
The company lodges its Annual Report to shareholders 30 June 2017. | 06/10/2017 |
The company releases its Corporate Governance Statement. | 06/10/2017 |
The company releases an Appendix 4G. | 06/10/2017 |
The securities of the company will be suspended from official quotation from the commencement of trading today, 2 October 2017, following failure to lodge its full year accounts for the period ended 30 June 2017 in accordance with ASX listing rules. | 02/10/2017 |
The suspension of trading in the securities of Anteo Diagnostics Limited (the "Company") will be lifted immediately, following receipt of an announcement regarding revised terms in relation to the acquisition of DIAsource ImmunoAssays S.A by the Company. Security Code: ADO | 06/01/2016 |
Anteo Diagnostics Limited has agreed revised terms to acquire 100% of the equity in global specialty diagnostics company, DIAsource ImmunoAssays S.A. (Belgium), in line with previously announced acquisition. The originally announced Purchase Price of €15.4m (A$23.7m), with a two year earn out to vendors, subject to achievement of financial business targets (up to a maximum of €7.3m) remains the same. The Purchase Price consideration (€15.4m) is now to be paid 50% in cash up-front (€7.7m) and the balance (€7.7m) to be paid via a deferred payment plan. | 06/01/2016 |
The securities of Anteo Diagnostics Limited (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement in relation to the proposed revision of terms of the proposed DIAsource acquisition. Security Code: ADO | 05/01/2016 |
name changed from Biolayer Corporation Limited | 25/11/2008 |
Your browser may reflect a date of printing in American format.
Purchases Sales
| DATE | DIRECTOR | NUMBER | PRICE | AMOUNT |
|---|---|---|---|---|
| 20/11/2018 | Jack Hamilton | 1,000,000 | $0.015 | $15,000 |
| 30/04/2018 | Jack Hamilton | 1,050,000 | $0.014 | $14,700 |
| 09/11/2017 | John Hurrell | 500,000 | $0.018 | $9,000 |
| 28/03/2014 | Geoffrey Cumming | -4,000,000 | $0.258 | $1,031,599 |
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Jack Hamilton | Non Exec Chairman | 01/04/2018 |
| Derek Thomson | CEO | 26/08/2019 |
| Tamara Mills | COO | 15/08/2016 |
| Duncan Cornish | CFO, Company Secretary | 28/02/2019 |
| Geoffrey Cumming | Non Exec Director | 02/04/2009 |
| Richard Martin | Director | 23/09/2005 |
| Matthew Sanderson | Director | 19/10/2017 |
Date of first appointment, title may have changed.
| NAME | TITLE | DATE OF APPOINTMENT | DATE OF RESIGNATION |
|---|---|---|---|
| Christopher Parker | CEO | 23/04/2018 | 26/08/2019 |
| Harley Frankfurt | CEO | 23/04/2019 | 22/07/2019 |
| Glenn McInally | CFO | 31/07/2017 | 28/02/2019 |
| Stefan Enderling | CEO | 01/01/2018 | 27/04/2018 |
| John Hurrell | Executive Chairman | 01/09/2017 | 31/03/2018 |
| Rolf Sickman | Non Exec Director | 29/01/2016 | 31/03/2018 |
| Alan Studley | Non Exec Director | 11/05/2017 | 16/11/2017 |
| Jef Vangenechten | CEO | 14/06/2016 | 01/09/2017 |
| Peter Harding-Smith | CFO | 04/10/2016 | 31/07/2017 |
| Mark Bouris | Non Exec Chairman | 05/08/2011 | 14/11/2016 |
| Sam Andersen | Non Exec Director | 13/05/2011 | 25/08/2016 |
| James Henderson | Non Exec Chairman | 13/05/2011 | |
| Lara Iacusso | Non Exec Director | 25/02/2011 | |
| Robert Gilmour | Director | 03/11/2010 | |
| Bruce Rathie | Non Exec Chairman | 03/07/2006 | 26/08/2009 |
| Peter Rayner | Non Exec Director | 03/07/2006 | 16/09/2008 |
| David Beins | CEO | 01/04/2006 | 13/06/2008 |
| Carrie Hillyard | Non Exec Director | 23/09/2005 | 15/04/2008 |
| Tony Evans | Non Exec Director | 03/07/2006 | 15/04/2008 |
| Stephen Erichsen | Non Exec Director | 03/09/2004 | 21/11/2006 |
| Kim McGrath | Non Exec Chairman | 30/04/2004 | 03/07/2006 |
| Jason Armstrong | Executive Director | 23/09/2005 | 03/07/2006 |
| Henry Stenning | Non Exec Director | 05/04/2004 | 23/09/2005 |
| John Maher | Non Exec Director | 28/10/2003 | 25/08/2004 |
| John Dunn | Managing Director | 05/07/2004 | |
| Lorna Stone | Chairman | 30/06/2004 | |
| Frank Burke | Chairman | 10/07/2001 | 31/12/2003 |
| Clemens Der Weegen | Executive Director | 01/07/1995 | 28/11/2003 |
| Julie Nutting | Non Exec Director | 20/08/2003 | |
| Jennifer Wily | Non Exec Director | 01/08/1999 | 20/06/2003 |
| Michael Houghton | Non Exec Director | 01/11/1998 | 19/08/2002 |
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
